QDEL vs. CLDX, NTLA, MYGN, VIVO, HSKA, XRAY, MMSI, HAE, NEOG, and ICUI
Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Celldex Therapeutics (CLDX), Intellia Therapeutics (NTLA), Myriad Genetics (MYGN), Meridian Bioscience (VIVO), Heska (HSKA), DENTSPLY SIRONA (XRAY), Merit Medical Systems (MMSI), Haemonetics (HAE), Neogen (NEOG), and ICU Medical (ICUI). These companies are all part of the "medical" sector.
Celldex Therapeutics (NASDAQ:CLDX) and QuidelOrtho (NASDAQ:QDEL) are both mid-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, institutional ownership, earnings, valuation, media sentiment, profitability, community ranking and analyst recommendations.
99.0% of QuidelOrtho shares are owned by institutional investors. 3.8% of Celldex Therapeutics shares are owned by insiders. Comparatively, 1.0% of QuidelOrtho shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
QuidelOrtho has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.
Celldex Therapeutics currently has a consensus target price of $66.00, indicating a potential upside of 93.89%. QuidelOrtho has a consensus target price of $59.00, indicating a potential upside of 32.79%. Given QuidelOrtho's stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than QuidelOrtho.
QuidelOrtho has a net margin of -61.65% compared to QuidelOrtho's net margin of -2,385.57%. Celldex Therapeutics' return on equity of 3.96% beat QuidelOrtho's return on equity.
In the previous week, QuidelOrtho had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 9 mentions for QuidelOrtho and 6 mentions for Celldex Therapeutics. QuidelOrtho's average media sentiment score of 1.37 beat Celldex Therapeutics' score of 0.57 indicating that Celldex Therapeutics is being referred to more favorably in the media.
Celldex Therapeutics received 160 more outperform votes than QuidelOrtho when rated by MarketBeat users. Likewise, 74.91% of users gave Celldex Therapeutics an outperform vote while only 67.28% of users gave QuidelOrtho an outperform vote.
Celldex Therapeutics has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500. Comparatively, QuidelOrtho has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500.
Summary
Celldex Therapeutics beats QuidelOrtho on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding QDEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
QuidelOrtho Competitors List
Related Companies and Tools
